Ticker Details
Aldeyra Therapeutics, Inc. Aldeyra Therapeutics Inc is biotechnology company focused on the development of products for inflammation, inborn errors of metabolism, and other diseases, related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes.
IPO Date:	April 28, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$108.33M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.20 | 3.31%
Avg Daily Range (30 D):	$0.15 | 6.04%
Avg Daily Range (90 D):	$0.17 | 4.42%

Institutional Daily Volume
Avg Daily Volume:	.57M
Avg Daily Volume (30 D):	4.73M
Avg Daily Volume (90 D):	2.25M

Trade Size
Avg Trade Size (Sh.):	145
Avg Trade Size (Sh.) (30 D):	217
Avg Trade Size (Sh.) (90 D):	168

Institutional Trades
Total Institutional Trades:	448
Avg Institutional Trade:	$1.7M
Avg Institutional Trade (30 D):	$.58M
Avg Institutional Trade (90 D):	$.76M
Avg Institutional Trade Volume:	.23M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.89M
Avg Closing Trade (30 D):	$.58M
Avg Closing Trade (90 D):	$.77M
Avg Closing Volume:	254.18K

News

Apr 15, 2026 @ 8:53 PM Bragar Eagel & Squire, P.C. Encourages Aldeyra The... Source: Bragar Eagel & Squire, P.C.

Apr 13, 2026 @ 6:56 PM ALDX Investor Alert: Aldeyra Therapeutics Securiti... Source: Levi & Korsinsky, Llp

Apr 12, 2026 @ 2:41 PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Aldeyra... Source: Rosen Law Firm

Apr 12, 2026 @ 2:01 PM ROSEN, THE FIRST FILING FIRM, Encourages Trip.com ... Source: Rosen Law Firm

Apr 10, 2026 @ 6:53 PM ALDX Investors Have Opportunity to Lead Aldeyra Th... Source: The Schall Law Firm

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-.56	$-.1	$-.56
Diluted EPS	$-.56	$-.1	$-.56
Revenue
Gross Profit
Net Income / Loss	$-33.85M	$-6.46M	$-33.85M
Operating Income / Loss	$-35.27M	$-6.67M	$-35.27M
Cost of Revenue
Net Cash Flow	$15.51M	$10.7M	$15.51M
PE Ratio